臨床泌尿器科68巻4号

2014年04月発行

増刊号特集 前立腺癌の診療ナビゲーション―わかりやすく丁寧に！ Ⅳ　前立腺癌の治療と問題点 《内分泌療法》

21．根治治療での補助ホルモン療法の実際と問題点―アジュバント・ホルモン療法

著者： 岡村菊夫¹

所属機関： ¹国立病院機構東名古屋病院泌尿器科

ページ範囲：P.209 - P.213

039


Q　外科的治療および放射線治療それぞれにおけるアジュバント・ホルモン療法の適応，実際，注意点について教えてください。


Point

●前立腺全摘除術後のアジュバント・ホルモン療法の意義は明らかではない。

●外照射療法に関しては，高リスク群では3年程度のアジュバント・ホルモン療法が薦められるが，中間リスク群ではネオアジュバントを含めた短期間のホルモン療法が有効と考えられる。

参考文献

1）日本泌尿器科学会（編）：前立腺癌診療ガイドライン，2012年版．金原出版，東京，2012

）　http://www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional

）prostate cancer　http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

4）Cooperberg MR, Broering JM and Carroll PR：Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101：878-887, 2009

5）D'Amico AV, Moul JW, Carroll PR, et al：Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95：1376-1383, 2003

6）Stephenson AJ, Scardino PT, Kattan MW, et al：Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25：2035-2041, 2007

7）Messing EM, Manola J, Yao J, et al：Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7：472-479, 2006

8）Briganti A, Karnes RJ, Da Pozzo LF, et al：Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN＋prostate cancer：results of a matched analysis. Eur Urol 59：832-840, 2011

9）Touijer KA, Mazzola CR, Sjoberg DD, et al：Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. 2013 Apr 10. pii：S0302-2838（13）00340-0. doi：10.1016/j.eururo.2013.03.053.［Epub ahead of print］

10）Williams SB, Gu X, Lipsitz SR, et al：Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer 117：4846-4854, 2011

11）Yokomizo A, Kawamoto H, Nihei K, et al：Randomized controlled trial to evaluate radiotherapy：endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy：Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol 35：34-36, 2005

12）Shipley WU, Hunt D, Lukka H, et al：Initial Report of RTOG 9601：a phase Ⅲ trial in prostate cancer：anti-androgen therapy（AAT）with bicalutamide during and after radiation therapy（RT）improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy（RP）with pT2-3, N0 disease, and elevated PSA levels. Int J Rad Oncol Biol Phys 78（Suppl）：S27, 2010

13）Parker C, Matthew RS, Catton C, et al：Radiotherapy and androgen deprivation in combination after local surgery（RADICALS）：a new Medical Research Council/National Cancer Institute of Canada phase Ⅲ trial of adjuvant treatment after radical prostatectomy. BJU Int 99：1376-1379, 2007

14）Iversen P, McLeod DG, See WA, et al：Casodex Early Prostate Cancer Trialists' Group：Antiandrogen monotherapy in patients with localized or locally advanced prostate Cancer：final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 105：1074-1081, 2010

15）Tunn F：The current status of intermittent androgen deprivation（IAD）therapy for prostate cancer：putting IAD under the spotlight. BJU Int 99（suppl 1）：19-22, 2007

16）Bolla M, van Tienhoven G, Warde P, et al：External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk：10-year results of an EORTC randomised study. Lancet Oncol 11：1066-1073, 2010

17）Pilepich MV, Winter K, Lawton CA, et al：Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma：long-term results of phase Ⅲ RTOG 85-31. Int J Radiat Oncol Biol Phys 61：1285-1290, 2005

18）Horwitz EM, Bae K, Hanks GE, et al：Ten-year follow-up of radiation therapy oncology group protocol 92-02：a phase Ⅲ trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26：2497-504, 2008

19）Bolla M, de Reijke TM, Van Tienhoven G, et al：Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360：2516-2527, 2009

20）Souhami L, Bae K, Pilepich M, et al：Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy：a secondary analysis of RTOG 85-31. J Clin Oncol 27：2137-2143, 2009

21）Zumsteg ZS, Spratt DE, Pei I, et al：A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013 Mar 23. doi：pii：S0302-2838（13）00257-1. 10.1016/j.eururo.2013.03.033.［Epub 2013 Mar 23.］

22）Zapatero A, Valcárcel F, Calvo FA, et al：Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer：does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? a GICOR study. J Clin Oncol 23：6561-6568, 2005